Sodium Thiosulfate
- Generic Name
- Sodium Thiosulfate
- Indication
⑴治疗氰化物中毒，与高铁血红蛋白形成剂联合应用；
⑵治疗降压药硝普钠过量中毒；
⑶治疗可溶性钡盐（如硝酸钡）中毒；
⑷治疗砷、汞、铋、铅等金属中毒，但首选二巯基类药物及依地酸类药物；
⑸作为非特异性抗炎药，用于皮炎、湿疹、荨麻疹、药物性皮炎、副银屑病的治疗【1.《糖皮质激素类药物临床应用指导原则》；2.《中西医结合系统药物治疗湿疹皮炎类皮肤病专家共识》2015；3.《临床诊疗指南皮肤病与性病分册》】。
Applied StemCell Launches Hypoimmunogenic hiPSC Products to Advance Allogeneic Cell Therapy Development
• Applied StemCell has introduced two new hypoimmunogenic human induced pluripotent stem cell (hiPSC) products designed to overcome immune rejection challenges in allogeneic cell therapy development.
• The products feature B2M/CIITA double knock-out modifications that eliminate HLA class I and II expression, significantly reducing the risk of T cell-mediated immune rejection in transplanted cells.
• Derived from CD34+ umbilical cord blood cells with low mutational burden, these research-use-only tools are isogenic matches to forthcoming GMP-grade versions, offering researchers a seamless transition from early research to clinical development.
NICE Recommends Pedmarqsi as First NHS Treatment for Cisplatin-Induced Hearing Loss in Children
• The National Institute for Health and Care Excellence (NICE) has recommended Pedmarqsi for preventing cisplatin-induced hearing loss in young patients aged 1 month to 17 years.
• Clinical trials demonstrated that Pedmarqsi reduces cisplatin-induced ototoxicity by approximately 50% compared to cisplatin alone, addressing a critical unmet need.
• Fennec Pharmaceuticals has an exclusive licensing agreement with Norgine Pharmaceuticals for commercialization in Europe, Australia, and New Zealand.
• The licensing agreement includes a $43 million upfront payment and potential additional payments up to $230 million, plus double-digit tiered royalties.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath